Recombinant Fusion Proteins

"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.

Descriptor ID	D011993
MeSH Number(s)	D12.776.828.300
Concept/Terms	Recombinant Fusion Proteins Recombinant Fusion Proteins Proteins, Recombinant Fusion Fusion Proteins, Recombinant Hybrid Proteins, Recombinant Hybrid Proteins, Recombinant Proteins, Recombinant Hybrid Recombinant Hybrid Proteins Chimeric Proteins, Recombinant Chimeric Proteins, Recombinant Proteins, Recombinant Chimeric Recombinant Chimeric Proteins

Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Recombinant Proteins [D12.776.828]
Recombinant Fusion Proteins [D12.776.828.300]

Below are MeSH descriptors whose meaning is related to "Recombinant Fusion Proteins".

Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".

Recombinant Fusion Proteins
CD4 Immunoadhesins
Transcription Activator-Like Effector Nucleases
Zinc Finger Nucleases

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.

Bar chart showing 453 publications over 30 distinct years, with a maximum of 30 publications in 2002

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	13	14
1997	2	22	24
1998	1	12	13
1999	0	17	17
2000	2	19	21
2001	4	23	27
2002	1	29	30
2003	3	10	13
2004	2	23	25
2005	5	22	27
2006	4	15	19
2007	4	20	24
2008	0	8	8
2009	7	16	23
2010	3	9	12
2011	4	7	11
2012	8	5	13
2013	10	6	16
2014	7	3	10
2015	10	14	24
2016	6	3	9
2017	7	7	14
2018	7	6	13
2019	6	7	13
2020	3	3	6
2021	3	3	6
2022	0	4	4
2023	1	5	6
2024	4	5	9
2025	2	0	2

Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.

Kalavar M, Sridhar J. Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. Curr Opin Ophthalmol. 2025 May 01; 36(3):189-198.

View in: PubMed
Momenaei B, Yonekawa Y, Abril P, McCullough R, Abbey AM. Outcomes of Intravitreal Aflibercept 8 mg in Eyes With Neovascular Age-Related Macular Degeneration Previously Treated With Faricimab. Ophthalmic Surg Lasers Imaging Retina. 2025 04; 56(4):206-211.

View in: PubMed
Kaufmann GT, Boucher N, Sharma C, Aggarwal N, Starr MR. Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration. Am J Ophthalmol. 2025 Feb; 270:172-182.

View in: PubMed
Tang J, Becker M, Lenhoff A, Chen W. Engineering of heterobifunctional biopolymers for tunable binding and precipitation of Strep-Tag proteins and virus-like nanoparticles. Biotechnol Bioeng. 2024 Dec; 121(12):3860-3868.

View in: PubMed
Hayashi M, Girdhar A, Ko YH, Kim KM, DePierro JA, Buchler JR, Arunprakash N, Bajaj A, Cingolani G, Guo L. Engineered NLS-chimera downregulates expression of aggregation-prone endogenous FUS. Nat Commun. 2024 09 10; 15(1):7887.

View in: PubMed
Lin TY, Hsieh YT, Garg SJ, Chen LJ, Chen KJ, Wu WC, Lai CC, Hwang YS, Kang EY. Systemic effects of anti-VEGF intravitreal injection in patients with age-related macular degeneration: A multi-institutional real-world study. Indian J Ophthalmol. 2024 11 01; 72(Suppl 5):S809-S815.

View in: PubMed
Dang S, Parke DW, Sodhi GS, Eichenbaum D, Nielsen J, Danzig C, Lalwani G, Moinfar N, London N, Kimura A, Jumper JM, Lord K, Sheth V, Pieramici D, Orlin A, Madson A, Horton M, Blim J, Cao JA, Thompson J, Khanna S, Wykoff CC, Shah AR. Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 08 01; 142(8):716-721.

View in: PubMed
Nanji K, Kennedy K, Fung M, Xie J, Hatamnejad A, Garg SJ, Wykoff CC, Chaudhary V. Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration. Can J Ophthalmol. 2025 02; 60(1):e92-e99.

View in: PubMed
Jabbour S, Paik JS, Aleppo G, Sharma P, Gomez Valderas E, Benneyworth BD. Switching to Tirzepatide 5?mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment. Endocr Pract. 2024 Aug; 30(8):701-709.

View in: PubMed
Cai CX, Nishimura A, Bowring MG, Westlund E, Tran D, Ng JH, Nagy P, Cook M, McLeggon JA, DuVall SL, Matheny ME, Golozar A, Ostropolets A, Minty E, Desai P, Bu F, Toy B, Hribar M, Falconer T, Zhang L, Lawrence-Archer L, Boland MV, Goetz K, Hall N, Shoaibi A, Reps J, Sena AG, Blacketer C, Swerdel J, Jhaveri KD, Lee E, Gilbert Z, Zeger SL, Crews DC, Suchard MA, Hripcsak G, Ryan PB. Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study. Ophthalmol Retina. 2024 08; 8(8):733-743.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement